US 11,865,209 B2
Method for preventing nasolacrimal duct obstruction
Kenneth Eli Morgenstern, Bryn Mawr, PA (US)
Assigned to KEM PATENT HOLDINGS, LLC, Bryn Mawr, PA (US)
Filed by KEM PATENT HOLDINGS, LLC, Bryn Mawr, PA (US)
Filed on Apr. 1, 2019, as Appl. No. 16/371,440.
Application 15/925,260 is a division of application No. 15/099,034, filed on Apr. 14, 2016, granted, now 9,962,332, issued on May 8, 2018.
Application 16/371,440 is a continuation of application No. 15/925,260, filed on Mar. 19, 2018, granted, now 10,245,226.
Application 15/099,034 is a continuation of application No. 14/225,087, filed on Mar. 25, 2014, granted, now 9,314,426, issued on Apr. 19, 2016.
Application 14/225,087 is a continuation of application No. 13/962,509, filed on Aug. 8, 2013, granted, now 8,722,012, issued on May 13, 2014.
Application 13/962,509 is a continuation of application No. 12/012,469, filed on Feb. 4, 2008, granted, now 8,529,871, issued on Sep. 10, 2013.
Application 12/012,469 is a continuation of application No. 11/112,553, filed on Apr. 25, 2005, granted, now 9,452,133, issued on Sep. 27, 2016.
Prior Publication US 2019/0224113 A1, Jul. 25, 2019
This patent is subject to a terminal disclaimer.
Int. Cl. A01N 59/08 (2006.01); A61K 33/14 (2006.01); A61K 9/00 (2006.01); A61K 33/18 (2006.01); A61K 33/40 (2006.01); A61K 45/06 (2006.01); A61K 51/00 (2006.01); A61K 33/20 (2006.01); A61K 9/06 (2006.01); A61K 9/08 (2006.01); A61K 47/02 (2006.01)
CPC A61K 9/0046 (2013.01) [A61K 9/0048 (2013.01); A61K 33/14 (2013.01); A61K 33/18 (2013.01); A61K 33/20 (2013.01); A61K 33/40 (2013.01); A61K 45/06 (2013.01); A61K 51/00 (2013.01); A61K 9/00 (2013.01); A61K 9/0012 (2013.01); A61K 9/0043 (2013.01); A61K 9/06 (2013.01); A61K 9/08 (2013.01); A61K 47/02 (2013.01)] 7 Claims
 
1. A method for reducing formation of fibrosis in at least one nasolacrimal duct of a patient that may occur upon the patient receiving radioactive iodine, the method comprising administering to the patient by topically delivering an ophthalmic composition comprising perchlorate anion to at least one eye of the patient, or instilling the ophthalmic composition directly into the at least one nasolacrimal duct or at least one lacrimal sac of the patient, wherein the perchlorate anion is at a concentration of about 40 mg/ml to about 400 mg/ml and the ophthalmic composition further comprises at least one of white petrolatum, mineral oil, lanolin, or polyethylene mineral oil gel.